<unk>  is a drug analogue of ritonavir, in which the valine moiety is exchanged for a 2-morpholinoethyl group, and the backbone hydroxyl group is removed. These changes effectively eliminate the anti-HIV activity of ritonavir while preserving its inhibitory effects on the CYP3A isozyme family of proteins.<unk>  is therefore able to increase plasma concentration of other coadministered anti-HIV drugs without the risk of causing<unk> -resistant mutations in the HIV virus. Synthesis<unk>  may be synthesized from any number of commercially available starting materials. The synthesis shown below utilizes L-methionine and bromoacetic acid as starting materials.
Cobicistat
Migalastat
Ganirelix
Oprelvekin
Udenafil
Vosoritide
Epitiostanol
Macitentan